Appeal No. 2005-0545
Application No. 09/989,019
for oral administration with foods and beverages to control
digestion and absorption of lipids and control and prevent obesity
(Lotte, pp. 4, 6 and 13). An example of a preferred lipase-
inhibiting agent is the flavonol quercetin (Lotte, p. 7).
De Simone teaches oral or topical administration (De Simone,
(Claims 7, 9 and 10) of compositions including carnitine
derivatives such as L-acetylcarnitine, L-isovalerylcarnitine and
L-propionylcarnitine, and pharmaceutically acceptable salts thereof,
to increase glucose uptake, reduce ketones and fatty acids, to
increase protein synthesis (De Simone, p. 1, middle para.), and for
therapeutic treatment of obesity and regeneration of cutaneous,
intestinal, hepatic and other tissue (De Simone, pp. 1-2, bridging
para.).
We find that each and every prior art reference cited by the
examiner pertains to therapeutic compositions for oral and/or
topical administration to control, prevent, reduce or relieve
accumulation of fat. Thus, we find that all of the cited prior art
references are analogous to the subject matter Pugliese claims.
We proceed to consider whether the combined teachings of
the prior art prima facie would have led persons having ordinary
skill in the art to make and use multicomponent compositions
comprising (1) quercetin or fisetin, (2) genistein or daidzein,
11
Page: Previous 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next
Last modified: November 3, 2007